U.S., March 10 -- ClinicalTrials.gov registry received information related to the study (NCT07458906) titled 'DLL3-Targeted PET/CT in Neuroendocrine Carcinoma' on Jan. 18.
Brief Summary: The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
Study Start Date: Dec. 01, 2025
Study Type: INTERVENTIONAL
Condition:
DLL3-expressing Tumors
PET / CT
Neuroendocrine Cancer
Intervention:
DIAGNOSTIC_TEST: Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
Participants will undergo DLL3-Targeted PET/CT imaging for the evaluation of tumor lesions....